Founder & CEO of GenQual Corp. (2009-). Co-founder, Saga Software, Inc. (2011). Sr. QC Analyst, Targeted Genetics Corp. (2003-2009). Patent: "Methods of Prognosing and Administering Treatment for Inflammatory Disorders"(Intnl Pat No. PCT/US2012/024448) Specializes in novel product design and innovations, defining key market opportunities, identifying mutually beneficial partner strategies, assay optimization & validation, statistical analysis.

Dr. Colton has broad technical and legal experience in the life science industry, including molecular diagnostics. He previously worked as a patent attorney managing domestic and international patents for corporations and research institutions. His scientific research includes genetic polymorphisms linked to vector-borne diseases such as malaria. He earned a Ph.D. from the University of Notre Dame and a J.D. from Brigham Young University.

Sr. Product Manager at Cerep and the Director of Technology Assessment and Discovery while at Targeted Genetics Corp. He currently serves at Abcam as a Scientific Support Supervisor. Dr. Paul received his Ph.D. in Molecular Virology at University of Calgary and he performed his post-doc studies in retrovirology at Oregon Health and Science University School of Medicine.